SCHEMBL29976261

SCHEMBL29976261

S=C=Nc1ccc(Cl)c(Cl)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.63
MAPK1 P28482 1/20 0.63
HTR3E A5X5Y0 2/20 0.47
HTR3B O95264 2/20 0.47
HTR3A P46098 2/20 0.47
HTR3D Q70Z44 2/20 0.47
HTR3C Q8WXA8 2/20 0.47
P2RY6 Q15077 2/20 0.45
MIF P14174 1/20 0.44
KMT2A Q03164 1/20 0.42
ITGB3 P05106 1/20 0.41
ITGAV P06756 1/20 0.41
PNMT P11086 1/20 0.41
MAPT P10636 3/20 0.40
CYP3A4 P08684 3/20 0.40
HSD17B10 Q99714 3/20 0.40
KDM4E B2RXH2 2/20 0.40
USP2 O75604 2/20 0.40
ALDH1A1 P00352 2/20 0.40
LTA P01374 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1052023 1.00 TDP1 (0.63) TDP1MAPK1HTR3EHTR3BHTR3A
SCHEMBL17289576 0.83 TDP1 (0.44) TDP1MAPK1HTR3EHTR3BHTR3A
SCHEMBL11415576 0.83 TDP1 (0.44) TDP1MAPK1HTR3EHTR3BHTR3A
SCHEMBL507208 0.81 MAPK1 (0.68) TDP1MAPK1HTR3EHTR3BHTR3A
SCHEMBL31044049 0.81 MAPK1 (0.68) TDP1MAPK1HTR3EHTR3BHTR3A
SCHEMBL13210766 0.81 TDP1 (0.42) TDP1MAPK1HTR3EHTR3BHTR3A
SCHEMBL11574824 0.81 TDP1 (0.42) TDP1MAPK1P2RY6MIFKMT2A
SCHEMBL62416 0.81 HTR3E (0.46) TDP1MAPK1HTR3EHTR3BHTR3A
SCHEMBL1018986 0.81 ITGB3 (0.46) TDP1MAPK1P2RY6MIFKMT2A
SCHEMBL19260919 0.81 TDP1 (0.42) TDP1MAPK1HTR3EHTR3BHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4139286-B1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AG (DE) 2025-02-26 EP disclosed
US-11964953-B2 Substituted aminothiazoles as DGKzeta inhibitors for immune activation BAYER AKTIENGESELLSCHAFT (DE) 2024-04-23 US disclosed
EP-4330258-A1 COMPOUNDS Pathios Therapeutics Limited (GB) 2024-03-06 EP disclosed
US-20230167078-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
US-20230139936-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-05-04 US disclosed
WO-2022229615-A1 COMPOUNDS Pathios Therapeutics Limited (GB) 2022-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230139936-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION DGKZ, DGKA, DGKG TDP1 2791/4885MAPK1 1541/4885HTR3E 2989/4885
US-20230167078-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION DGKZ, DGKA, DGKG TDP1 2791/4885MAPK1 1541/4885HTR3E 2989/4885
US-11964953-B2 Substituted aminothiazoles as DGKzeta inhibitors for immune activation DGKZ, DGKA, DGKG TDP1 2791/4885MAPK1 1541/4885HTR3E 2989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.